Samsara BioCapital’s ALX Oncology ALXO Stock Holding History

Samsara BioCapital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-262,786	Closed	-$1.19M	–	48
2023 Q1	$1.19M	Hold	262,786	–	–	0.25%	39
2022 Q4	$2.96M	Hold	262,786	–	–	0.64%	27
2022 Q3	$2.52M	Hold	262,786	–	–	0.59%	33
2022 Q2	$2.13M	Hold	262,786	–	–	0.57%	34
2022 Q1	$4.44M	Buy	+262,786	New	+$4.49M	1.12%	23

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Samsara BioCapital's ALXO Position: Q2 2023 in Review

Samsara BioCapital sold out of ALX Oncology (ALXO) in Q2 2023, closing a stake of 262,786 shares — an estimated $1.19M sold.

Samsara BioCapital first reported a position in ALXO in Q1 2022 and held it in 5 quarters. The position peaked at $4.44M in Q1 2022. 75 funds tracked by Wall St. Rank hold ALXO as of Q2 2023.

Samsara BioCapital reported no remaining ALX Oncology position as of Q2 2023 after selling out during the quarter.
Samsara BioCapital sold 262,786 ALX Oncology shares in Q2 2023, an estimated $1.19M.
Samsara BioCapital first reported a position in ALX Oncology in Q1 2022 and held it in 5 quarters.
Samsara BioCapital's ALX Oncology position peaked at $4.44M in Q1 2022.
75 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2023.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.